SANUWAVE Health Earnings Call Transcripts
Fiscal Year 2026
-
Wound care is undergoing a payer-driven shift to evidence-based medicine, creating opportunities for high-efficacy, cost-effective solutions. UltraMIST’s strong clinical evidence, expanding reimbursement, and consumables-driven model position it for growth, especially as it targets large enterprise accounts.
-
The meeting covered director elections, auditor ratification, and executive compensation votes. Quorum was met, voting was conducted online, and results will be disclosed in a Form 8-K. Only meeting-related questions were addressed during the Q&A.
-
Record Q1 revenue and strong consumables growth were achieved despite a market freeze from CMS pricing changes. Guidance for 2026 remains robust, with expectations for a stronger second half driven by seasonality and large account engagement.
Fiscal Year 2025
-
Record Q4 and full-year revenue growth driven by UltraMIST system sales and consumables, despite industry disruption from CMS reimbursement changes. Strategic channel shift to resellers and strong cash position support 2026 growth outlook of 16%–25%.
-
Q3 2025 set new revenue and unit sales records, with 22% year-over-year growth and strong gross margins. Net income swung to $10.3 million, aided by non-cash gains and a patent sale. Guidance for Q4 anticipates continued record growth as reimbursement uncertainty eases.
-
The virtual meeting covered director elections, auditor ratification, equity plan amendment, and executive compensation votes. A quorum was present, voting was completed online, and results will be disclosed in a Form 8-K. No stockholder questions were submitted.
-
Q2 2025 revenue rose 42% year-over-year to $10.2M, with gross margin up to 78.3% and strong UltraMIST adoption. Guidance for Q3 is $12M–$12.7M, with new applicator design expected to further boost margins in 2026. Senior debt refinancing and expanded sales force support continued growth.
-
Q1 2025 saw 61% revenue growth, record system placements, and improved gross margins, exceeding guidance. Net loss increased due to non-cash expenses, but adjusted EBITDA turned positive. Guidance for Q2 and full-year 2025 remains strong.
Fiscal Year 2024
-
Record Q4 and full-year revenue achieved with strong growth in system placements and consumables. Gross margin expanded to 77.9%, and adjusted EBITDA improved significantly. Guidance for 2025 targets 50% revenue growth, with a strengthened balance sheet and expanded salesforce.
-
Record Q3 revenue and margin expansion were driven by strong UltraMIST sales and recurring revenue growth. Debt was repaid, capital structure simplified, and guidance for Q4 and full-year 2024 was raised, with continued focus on U.S. growth and operational improvements.
-
Record Q2 2024 revenues grew 53% year-over-year to $7.2M, with gross margin at 73% and net income of $6.6M, driven by strong UltraMIST sales and operational improvements. Guidance for Q3 revenue growth was raised to 65%-75% year-over-year.
-
The merger aims to simplify the capital structure and enable national exchange listing, with recent debt repayment and ongoing efforts to secure a Cboe BZX listing. Strong revenue growth continues, and the company retains flexibility to pursue alternative uplisting options.